<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0045503</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1920</journal-id>
<journal-id journal-id-type="nlm-ta">Brain Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Brain Res.</journal-id>
<journal-title-group>
<journal-title>Brain research</journal-title>
</journal-title-group>
<issn pub-type="ppub">0006-8993</issn>
<issn pub-type="epub">1872-6240</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27060768</article-id>
<article-id pub-id-type="pmc">5053850</article-id>
<article-id pub-id-type="doi">10.1016/j.brainres.2016.03.051</article-id>
<article-id pub-id-type="manuscript">NIHMS780210</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Drug discovery using neurons derived from patients</article-title>
<subtitle>Studying Human Disease Using Human Neurons</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ahfeldt</surname>
<given-names>Tim</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Litterman</surname>
<given-names>Nadia K.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rubin</surname>
<given-names>Lee L.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<aff id="A1"><label>1</label> Department of Stem Cells and Regenerative Biology, Harvard University, Cambridge MA , USA, <email>lee_rubin@harvard.edu</email>, Fax: 617-495-3961</aff>
</contrib-group>
<pub-date pub-type="nihms-submitted">
<day>30</day>
<month>4</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>06</day>
<month>4</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<day>01</day>
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>2</month>
<year>2018</year>
</pub-date>
<volume>1656</volume>
<fpage>40</fpage>
<lpage>48</lpage>
<!--elocation-id from pubmed: 10.1016/j.brainres.2016.03.051-->
<abstract>
<p id="P1">Utilizing patient derived cells has enormous promise for discovering new drugs for diseases of the nervous system, a goal that has been historically quite challenging. In this review, we will outline the potential of human stem cell derived neuron models for assessing therapeutics and high-throughput screening and compare to more traditional drug discovery strategies. We summarize recent successes of the approach and discuss special considerations for developing human stem cell based assays. New technologies, such as genome editing, offer improvements to help overcome the challenges that remain. Finally, human neurons derived from patient cells have advantages for translational research beyond drug screening as they can also be used to identify individual efficacy and safety prior to clinical testing and for dissecting disease mechanisms.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>